miniDOX Chemotherapy for Advanced Gastric Cancer

Share this content:

the Cancer Therapy Advisor take:

For patients with advanced gastric cancer, chemotherapy can improve rates of overall survival. The combination of docetaxel, oxaliplatin, and capecitabine has shown to be a treatment regimen worth investigation.

Researchers sought to study this combination in patients with PS ECOG of 2 who were age 70 or older and had weight loss between 10% and 25%—these patients were defined as “suboptimal.” The researchers studied 43 patients with advanced gastric cancer who met “suboptimal” criteria who were previously untreated.

These patients received the “miniDOX” treatment regimen, which consisted of docetaxel 40 mg/m2 iv, day 1; oxaliplatin 80 mg/m2 iv, day 1; capecitabine 625 mg/m2 po bid, day 1 to day 21, every 21 days; after six courses, only capecitabine was maintained.

The primary endpoint of the study was response rate. Secondary study endpoints were overall survival, progression-free survival, and adverse events. Twelve patients has a PS ECOG of 2; 23 patients had weight loss between 10% and 25%; the median age of patients was 73.3 years (range 40-87; 28 patients were age 70 or older); 32 patients were male. Grade 3-4 adverse events included neutropenia (5 patients), febrile neutropenia (3 patients), pulmonary embolism (4 patients; 3 of which suffered sudden death),  diarrhea (9 patients), paronychia (2 patients), ictus (1 patients), renal failure (1 patients, patient was diagnosed with infection/bacteriemia and died), hand-foot syndrome (4 patients), and asthenia (5 patients).

One patient experienced complete response, 23 patients experienced partial response (response rate: 56%). Three patients experienced disease progression. Median and 1-year progression-free survival was 5.5 months (18%) and overall survival was 13.3 months (52%).

The researchers concluded that toxicity associated with miniDOX was of concern but the treatment proved to be worthy of further research in patients with advanced gastric cancer who are classified as “suboptimal.”

miniDOX Chemotherapy for Patients with Advanced Gastric Cancer
For patients with advanced gastric cancer, chemotherapy can improve rates of overall survival.
The authors defined "suboptimal" pts as those with PS ECOG = 2, weight loss 10-25 % and/or age ≥70 years. This population is usually underrepresented in AGC clinical trials. Although miniDOX's toxicity (mainly PE) has been important, its activity has been promising in "suboptimal" pts with AGC, and this combination should be further investigated in this setting.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs